ALVR Shareholders Who Lost Money Should Contact Robbins LLP for Information About the AlloVir, Inc. Class Action
For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
- For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
- Specifically, AlloVir said it was discontinuing the posoleucel Phase 3 studies after pre-planned analyses concluded they wouldn’t meet their primary endpoints.
- What Now: Similarly situated shareholders may be eligible to participate in the class action against AlloVir, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.
- A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.